Since the beginning of this year, there have been frequent
personnel changes in multinational enterprises.
Since entering October, many multinational pharmaceutical companies, including Merck and GSK, have reported executive
changes.
Recently, Merck China announced that Brecht Vanneste, the current Managing Director of Merck Belgium and Luxembourg, has taken over as head of Merck China's Oncology Business Unit, effective October 24
, 2022.
It is understood that Brecht Vanneste joined Merck - Belgium in February 1999, starting as a product manager
.
During his 23 years at Merck, Brecht Vanneste served as Head of External Affairs at Merck-Belgium, Product Director for Alzheimer's Disease in Europe and Canada, and Regional Marketing Head for Cardiovascular Products for the Swiss market
.
In March 2019, he was appointed Vice President and Managing Director
of Merck Belgium and Luxembourg.
On October 25, several foreign media reported that Roger Connor, president of GSK Vaccines and Global Health, was about to leave
.
It is worth noting that at the same time as Roger's departure, GSK also made adjustments
to some executives.
In this role, Chief Commercial Officer Luke Miels will have overall responsibility for strategic commercial product development for vaccines (in collaboration with R&D and supply), while continuing to be responsible for the development of strategic specialty and general drug products and the commercialization
of product portfolios.
RIgis Simard, President of Global Supply Chain, is responsible for the supply
of vaccines and pharmaceuticals.
Deborah Waterhouse, CEO of ViiV Healthcare, will have overall responsibility for GSK Global Health
.
With this change, GSK CEO Emma Walmsley has a streamlined executive team following the Haleon spin-off.
.
.
.
.
.
.
The industry believes that from the perspective of frequent personnel changes in multinational pharmaceutical companies, the current policy environment of the pharmaceutical industry is constantly intensifying, and enterprises are also actively making strategic adjustments
.
It is understood that in this context, in addition to frequent changes in senior executives, the pace of reduction of multinational pharmaceutical companies is also accelerating
.
According to incomplete statistics, since 2022, 87 foreign biotechnology companies have reduced their staff
.
Among them, there are many large pharmaceutical companies
such as Eisai, Biogen, Novartis, Sanofi, Merck, Gilead, and Daiichi Sankyo.
For example, on October 6, Cyclerion Therapeutics announced that it would cut 45 percent of its workforce, which is expected to save Cyclerion $4.
1 million annually, and the company will shift its focus to mitochondrial diseases
.
In addition to reducing the headcount to about 16, executives plan to seek cooperation
with pipeline projects focused on kidney and neuropsychiatric disorders.
On October 4, OncoSec, which focuses on the development of intra-tumor immunotherapy, announced that it will cut its workforce by 45% to reduce operating expenses to prioritize the development of its main pipeline product, TAVO (TAVO-ep™).
TAVO uses electroporation technology to generate a controlled local expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors
throughout the body.
On the whole, the reasons for the reduction of multinational pharmaceutical companies mainly include cost savings, extending the time of capital reserves, as well as business focus transfer and project pipeline adjustment.
Among them, the failure of clinical trials of new drugs or the rejection of the FDA has a huge
impact on pharmaceutical companies.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
